Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 105.45M | 84.04M | 56.63M | 34.16B | 32.26M | 25.38M |
Gross Profit | 58.84M | 40.09M | 26.36M | 16.59B | 14.80M | 11.87M |
EBITDA | 1.29M | 2.84M | 2.58M | 6.43M | 6.27M | 5.93M |
Net Income | -10.82M | -4.31M | 20.11M | 4.41B | 8.90M | 5.09M |
Balance Sheet | ||||||
Total Assets | 111.34M | 96.39M | 83.65M | 40.90M | 35.15M | 26.19M |
Cash, Cash Equivalents and Short-Term Investments | 21.74M | 11.32M | 7.11M | 7.83M | 8.54M | 3.19M |
Total Debt | 6.68M | 10.91M | 11.74M | 3.89M | 2.78M | 2.38M |
Total Liabilities | 63.66M | 42.87M | 26.07M | 11.94M | 9.93M | 10.04M |
Stockholders Equity | 47.68M | 53.52M | 57.58M | 28.96M | 25.22M | 16.15M |
Cash Flow | ||||||
Free Cash Flow | 18.02M | 4.93M | -4.09M | -2.40M | 6.01M | 2.86M |
Operating Cash Flow | 19.09M | 7.46M | -3.28M | 3.34M | 6.51M | 3.19M |
Investing Cash Flow | -954.76K | -2.40M | -809.65K | -5.74M | -498.57K | -262.78K |
Financing Cash Flow | -4.78M | -825.74K | 3.39M | 1.70M | -667.13K | -869.83K |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
82 Outperform | $655.91M | 7.98 | 27.44% | ― | 3.86% | -2.60% | |
70 Outperform | $1.49B | -464.85 | -3.22% | ― | 132.35% | 97.34% | |
69 Neutral | $1.25B | 10.05 | 17.78% | ― | 1.37% | -18.10% | |
68 Neutral | $741.00M | ― | -20.42% | ― | 58.70% | -152.33% | |
54 Neutral | $724.63M | -8.68 | 89.60% | ― | -24.38% | -94.72% | |
48 Neutral | $520.12M | -35.04 | -3.04% | ― | -4.21% | 7.78% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
Elite Pharmaceuticals reported significant financial growth for the first quarter of fiscal year 2026, ending June 30, 2025, with revenues reaching $40.2 million, marking a 114% increase from the previous year. This growth was largely driven by the successful launch of lisdexamfetamine products and strong performance in their existing product lines, resulting in a 462% rise in operating profits to $21.7 million.
Elite Pharmaceuticals announced that it will release its first quarter financial results for fiscal year 2026 on August 14, 2025, and will host a conference call on August 15, 2025, to discuss these results and provide a business update. This announcement is significant for stakeholders as it provides insights into the company’s financial health and strategic direction.
Elite Pharmaceuticals, Inc. reported a significant financial performance for the fiscal year ended March 31, 2025, with consolidated revenues reaching $84.0 million, marking a 48% increase from the previous year. The company’s operating profits rose by 81% to $19.6 million, driven by the successful launch of lisdexamfetamine products and growth in Elite’s existing product lines.
Elite Pharmaceuticals announced it will release its financial results for the fiscal year ending March 31, 2025, on June 30, 2025. A conference call will be held on July 1, 2025, to discuss these results and provide a business update, indicating a focus on transparency and stakeholder engagement.
On June 16, 2025, Elite Pharmaceuticals announced positive results from a pivotal bioequivalence study for an undisclosed generic anticoagulant drug, showing it is equivalent to the branded product. This finding is significant as there is currently no generic version on the market, and the branded product has a patent listed in the Orange Book. Elite plans to file an Abbreviated New Drug Application with the FDA, which could impact the market by introducing a generic alternative, pending successful filing, FDA approval, and patent considerations.